Semaglutide · adverse-event profile · research use only
Semaglutide side effects, as the STEP trials actually reported them.
Semaglutide is the most-studied GLP-1 agonist for weight management, so its adverse-event profile is documented in detail across the STEP trial program rather than guessed. This page reproduces that data as a research reference: the gastrointestinal events that define the class, a detail most summaries omit — the very different durations of each event — and the way a pure GLP-1 agonist's profile differs from tirzepatide's dual mechanism and retatrutide's triple mechanism. One honesty note: Titan does not stock semaglutide. It appears here as the single-receptor reference point for the triple-agonist retatrutide, which Titan does carry. It is a summary of clinical-trial data, not a human-use protocol or medical advice.
GI events dominate the profile
In the pooled STEP 1–3 analysis, semaglutide 2.4 mg versus placebo produced nausea 43.9% vs 16.1%, diarrhea 29.7% vs 15.9%, vomiting 24.5% vs 6.3% and constipation 24.2% vs 11.1%. The overwhelming majority — about 98% — were mild to moderate. Gastrointestinal tolerability is the single defining feature of the GLP-1 class, and semaglutide is the reference case for it.
How the three compare →The events don't all last the same length
This is the detail most summaries miss. In the STEP pooled data the median duration of each event was strikingly different: constipation ~47 days, nausea ~8 days, diarrhea ~3 days and vomiting ~2 days. So vomiting and diarrhea are brief flares, while constipation is the slow, lingering event — a distinction that matters far more for understanding the profile than a single 'GI side effects' bucket. Knowing which event is transient and which persists is the point.
Escalation schedule →They cluster in the escalation weeks
As with the class, the GI events occurred most commonly during or shortly after dose titration. In STEP 1, discontinuation due to adverse events was 7.0% on semaglutide vs 3.1% on placebo, and GI-specific discontinuation across STEP 1–3 was 4.3% vs 0.7% — with most of those occurring in the dose-escalation period. The published guidance is that delaying a step-up by four weeks can help a dose settle before advancing.
Titration reference →Weight loss was independent of the side effects
A mediation analysis in the STEP data found the weight-loss effect was unrelated to whether a participant experienced gastrointestinal side effects — the benefit did not depend on being nauseated. That directly contradicts the common assumption that the GI effects are 'how it works.' It is one of the more useful findings in the semaglutide literature and applies conceptually across the incretin class.
How long it takes to work →Why the comparator here is retatrutide
Semaglutide activates one receptor (GLP-1). Tirzepatide adds GIP; retatrutide — the compound Titan actually stocks — adds a third arm, glucagon. Reading semaglutide's table shows the single-receptor baseline: adding receptors tends to shift the GI signature (tirzepatide trades some nausea for more diarrhea) and, with retatrutide's glucagon arm, introduces non-GI effects like a heart-rate rise and dysesthesia. Semaglutide is the clean one-receptor reference, not a product Titan sells.
Retatrutide side effects →Research-use framing
Every figure here describes adverse events observed in human clinical trials of semaglutide and is reproduced as a research reference for laboratory and in-vitro modelling — not as a prediction of what any individual would experience, and not as instructions for human use. Titan does not supply semaglutide; it is referenced only as the single-receptor comparator for the in-stock triple agonist retatrutide, which Titan supplies strictly as a research-use-only reagent, not for human or animal consumption. Nothing here is medical advice.
Research-use policy →The detail, in plain terms
The adverse-event table, at a glance.
Rates below are drawn from the pooled STEP 1–3 analysis of semaglutide 2.4 mg versus placebo, reproduced as a research reference. Exact figures vary by study and cohort. Titan does not stock semaglutide.
- Nausea
- 43.9% vs 16.1% placebo; median duration ~8 days; concentrated in escalation.
- Diarrhea
- 29.7% vs 15.9% placebo; median duration ~3 days — a brief flare.
- Vomiting
- 24.5% vs 6.3% placebo; median duration ~2 days — the shortest-lived.
- Constipation
- 24.2% vs 11.1% placebo; median duration ~47 days — the lingering event.
- Severity
- ~98% of GI events mild to moderate.
- Discontinuation (GI)
- 4.3% vs 0.7% placebo across STEP 1–3; most during dose escalation.
- Discontinuation (all AE)
- 7.0% vs 3.1% placebo (STEP 1).
- Weight loss vs GI events
- Independent — mediation analysis found benefit did not depend on GI side effects.
Questions researchers ask
Before you order.
- What are the most common semaglutide side effects?
- In the pooled STEP 1–3 analysis of semaglutide 2.4 mg, the most frequent were gastrointestinal: nausea (about 44% vs 16% placebo), diarrhea (about 30%), vomiting (about 25%) and constipation (about 24%). About 98% were mild to moderate. These are human clinical-trial figures reproduced as a research reference, not medical advice.
- How long do semaglutide side effects last?
- The STEP data shows the events have very different durations: median constipation about 47 days, nausea about 8 days, diarrhea about 3 days and vomiting about 2 days. So vomiting and diarrhea tend to be brief flares while constipation is the slow, lingering event. This distinction is more informative than lumping everything into one 'GI side effects' category.
- Do the side effects mean it's working?
- No. A mediation analysis in the STEP program found the weight-loss effect was unrelated to whether a participant experienced gastrointestinal side effects — the benefit did not depend on being nauseated. This contradicts the common assumption that the GI effects are the mechanism of benefit, and the finding applies conceptually across the incretin class.
- Why does this page point to retatrutide instead of semaglutide?
- Because Titan stocks retatrutide, not semaglutide. Semaglutide activates one receptor (GLP-1); tirzepatide adds GIP; retatrutide adds a third arm, glucagon. Semaglutide's well-documented table is the clean single-receptor baseline that the dual and triple agonists build on — adding receptors shifts the GI signature and, with retatrutide, introduces non-GI effects like a heart-rate rise. This page does not imply Titan sells semaglutide.
- Is semaglutide approved for human use?
- Semaglutide is an FDA-approved drug, but Titan does not supply it, and research-grade material is not a substitute for a prescribed medicine. Titan Peptide Lab supplies retatrutide strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption. The adverse-event data here summarises published clinical research and is not medical or dosing advice.